Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01647789 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT01647789 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 31 participants.
The verdict
NCT01647789, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study was supposed to have assessed the safety and preliminary antitumor activity of CFG920, a new CYP17 inhibitor in castration resistant prostate cancer patients who are abiraterone naive or abiraterone resistant. The study was terminated after Phase I (dose escalation phase) and Phase II part of the study was not initiated. Novartis voluntarily terminated this study and hence stopped further enrollment of patients into this study. As the decision to terminate the study was not due to any safety issues, the patients enrolled in the study by the time of this decision were allowed to continue with treatment per the protocol.
Interventions
- DRUG CFG920
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2012-12-04 |
| Est. Completion | 2016-02-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01647789
The ClinicalTrials.gov registry entry for NCT01647789 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CFG920 is the first listed.
NCT01647789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01647789 about?
NCT01647789 is a clinical study titled "A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer". This study was supposed to have assessed the safety and preliminary antitumor activity of CFG920, a new CYP17 inhibitor in castration resistant prostate cancer patients who are abiraterone naive or abiraterone resistant. The study was terminated after Phase I (dose escalation phase) and Phase II pa...
What is the current status of trial NCT01647789?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2012-12-04. Estimated completion is 2016-02-03.
What interventions are being tested in trial NCT01647789?
The interventions under investigation include: CFG920 (DRUG).
Who is sponsoring clinical trial NCT01647789?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.